SAFC® and Novozymes Biopharma Extend Joint Agreement for Exclusive Distribution of Long®R3 Growth Factor
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
SAFC® and Novozymes Biopharma DK A/S has announced a 10-year extension of their joint agreement under which SAFC retains exclusive marketing and distribution rights for Novozymes Biopharma’s LONG®R³IGF-I (LONG®R3) growth factor used for industrial cell culture applications.
The growth factor is manufactured specifically for customers in the cell culture market, to enable them to reduce operational and regulatory complexity and minimize manufacturing risk.
LONG®R3 is expected to enhance the productivity and performance of industrial cell culture processes, replacing insulin in cell culture, specifically binding to type I IGF receptors to stimulate cell growth and support survival in serum-free media.
The growth factor offers customers a range of benefits to reduced complexity of manufacturing processes. LONG®R3 provides increased cell density, higher viability and extended culture duration, without compromising on safety or regulatory compliance.
Michael D. James, marketing manager, SAFC, said, “SAFC is thrilled to continue our collaboration with Novozymes Biopharma. This exclusive 10-year agreement is expected to enhance SAFC’s position as a critical raw material supplier into the biologic and vaccine markets. It is exciting to see how the attributes of LONG®R3 meet key development and manufacturing challenges as cell culture processes continue to become more sophisticated.”
Peter Rosholm, vice president, Novozymes Biopharma, said: “Novozymes Biopharma is very pleased to extend this successful partnership with SAFC. We are committed to supplying quality products for use in cell culture applications that reduce operational and regulatory complexity and minimize manufacturing risk. The outlook for LONG®R3 is extremely positive as it uniquely offers both potency and innovation and we look forward to working closely with SAFC to service customers in this market.”
The growth factor is manufactured specifically for customers in the cell culture market, to enable them to reduce operational and regulatory complexity and minimize manufacturing risk.
LONG®R3 is expected to enhance the productivity and performance of industrial cell culture processes, replacing insulin in cell culture, specifically binding to type I IGF receptors to stimulate cell growth and support survival in serum-free media.
The growth factor offers customers a range of benefits to reduced complexity of manufacturing processes. LONG®R3 provides increased cell density, higher viability and extended culture duration, without compromising on safety or regulatory compliance.
Michael D. James, marketing manager, SAFC, said, “SAFC is thrilled to continue our collaboration with Novozymes Biopharma. This exclusive 10-year agreement is expected to enhance SAFC’s position as a critical raw material supplier into the biologic and vaccine markets. It is exciting to see how the attributes of LONG®R3 meet key development and manufacturing challenges as cell culture processes continue to become more sophisticated.”
Peter Rosholm, vice president, Novozymes Biopharma, said: “Novozymes Biopharma is very pleased to extend this successful partnership with SAFC. We are committed to supplying quality products for use in cell culture applications that reduce operational and regulatory complexity and minimize manufacturing risk. The outlook for LONG®R3 is extremely positive as it uniquely offers both potency and innovation and we look forward to working closely with SAFC to service customers in this market.”
